TFF Pharmaceuticals Q2 2024 Earnings Report

TFF Pharmaceuticals EPS Results

• Actual EPS: -$1.22
• Consensus EPS: -$1.70
• Beat/Miss: Beat by +$0.48
• One Year Ago EPS: N/A

TFF Pharmaceuticals Revenue Results

• Actual Revenue: $0.65 million
• Expected Revenue: $0.15 million
• Beat/Miss: Beat by +$500.00 thousand
• YoY Revenue Growth: N/A

TFF Pharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 8/14/2024
• Time: N/A

TFF Pharmaceuticals (NASDAQ:TFFP), a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.